Gt biopharma issues open letter to shareholders detailing recent activities

Brisbane, california, feb. 02, 2023 (globe newswire) -- gt biopharma, inc. (the “company” or “gtb”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, issued an open letter from the ceo to shareholders, detailing the company's recent activities. the full letter is published below:
GTBP Ratings Summary
GTBP Quant Ranking